OBJECTIVE-Activation of the nuclear hormone receptor peroxisome proliferator-activated receptor (PPAR)-d has been shown to improve insulin resistance, adiposity, and plasma HDL levels. Several studies have reported that activation of PPARd is atheroprotective; however, the role of PPARd in renal function remains unclear. Here, we report the renoprotective effects of PPARd activation in a model of streptozotocin-induced diabetic nephropathy.
RESULTS-GW0742 decreased urinary albumin excretion without altering blood glucose levels. Macrophage infiltration, mesangial matrix accumulation, and type IV collagen deposition were substantially attenuated by GW0742. The gene expression of inflammatory mediators in the kidney cortex, such as monocyte chemoattractant protein-1 (MCP-1) and osteopontin (OPN), was also suppressed. In vitro studies demonstrated that PPARd activation increased the expression of anti-inflammatory corepressor B-cell lymphoma-6, which subsequently suppressed MCP-1 and OPN expression.
CONCLUSIONS-These findings uncover a previously unrecognized mechanism for the renoprotective effects of PPARd agonists and support the concept that PPARd agonists may offer a novel therapeutic approach for the treatment of diabetic nephropathy. Diabetes 60: [960] [961] [962] [963] [964] [965] [966] [967] [968] 2011 T he increasing prevalence of diabetic nephropathy worldwide is a major societal issue because of the enormous expense associated with kidney replacement therapy (1) . The pathogenesis of diabetic nephropathy is complex and involves multiple pathways that lead to kidney injury, including the polyol pathway (2) , protein kinase C (3), advanced glycation end products (4) , and transforming growth factor (TGF)-b (5).
In addition, inflammation is now recognized to play an important role in the development of diabetic nephropathy (6, 7) . In this condition, the accumulation of macrophages and increased expression of cell adhesion molecules are observed in renal biopsy specimens from patients with diabetic nephropathy (8) . We have demonstrated that inflammation in diabetic nephropathy can be ameliorated by inhibiting macrophage infiltration in intercellular adhesion molecule-1 (ICAM-1) and macrophage scavenger receptor-A (SR-A) knockout mice (9, 10) . Therefore, inflammation could be a major therapeutic target of diabetic nephropathy.
There is an increasing body of evidence suggesting that a subfamily of nuclear hormone receptor transcription factors, namely the peroxisome proliferator-activated receptors (PPARs) (PPARg, PPARa, and PPARd), may play important roles in the pathogenesis of metabolic syndrome, obesity, and diabetes (11) . PPARs are also implicated in many renal pathophysiological conditions, including diabetic nephropathy and glomerulosclerosis (12) . Synthetic PPARg and PPARa agonists, such as thiazolidinediones and fibrates, improve the glycemic control in type 2 diabetic patients and lower the serum triglyceride levels in hyperlipidemic patients. In addition, we and other investigators have reported that PPARg and PPARa agonists are also beneficial in diabetic nephropathy (13) (14) (15) . Although atheroprotective effects of PPARd agonists have been reported (16, 17) , there are no reports regarding the effects of PPARd agonists on diabetic nephropathy.
The purpose of the current study was to investigate the hypothesis that activation of PPARd prevents the development of diabetic nephropathy by inhibiting inflammatory processes, including chemokine/cytokine expression and macrophage infiltration.
RESEARCH DESIGN AND METHODS
Experimental protocol. Male C57BL/6J mice were purchased from Charles River (Yokohama, Japan). Eight-week-old mice were divided into three groups: 1) nondiabetic control mice (control; n = 6), 2) streptozotocin (STZ)-induced diabetic mice (DM; n = 7), and 3) diabetic mice treated with PPARd agonist GW0742 (DM+GW0742; n = 7). GW0742 mice were purchased from SigmaAldrich (Tokyo, Japan). Diabetes was induced by peritoneal injection of 200 mg/kg STZ (Sigma-Aldrich) in citrate buffer (pH 4.5). Blood glucose was measured by the glucose oxidase method at 3 and 7 days after STZ injection, and only mice with blood glucose concentrations .16 mmol/L were used in the study. Mice in the control group were injected with citrate buffer. The DM+GW0742 group received 1 mg/kg/day of GW0742 by gavage for 8 weeks. All mice had free access to standard diet and tap water. All procedures were performed according to the Guidelines for Animal Experiments at Okayama University Medical School, Japanese Government Animal Protection and Management Law (No. 105), and Japanese Government Notification on Feeding and Safekeeping of Animals (No. 6). Mice were killed at 8 weeks after FIG. 1. Time course of changes in UAE and PPARd mRNA and protein expression in the kidneys. A: The UAE increased progressively in the untreated diabetic (DM) group during the 8-week observation period after the induction of diabetes. GW0742 treatment (DM+GW0742) significantly reduced UAE at 8 weeks compared with the DM group. Control, nondiabetic control mice. Data are means 6 SE. *P < 0.01 for DM vs. DM+GW0742. B: Renal PPARd mRNA expression was significantly increased in the DM group compared with the control group. Data are means 6 SE. *P < 0.05. C: Localization of renal PPARd protein expression by immunohistochemistry. PPARd protein expression was predominantly localized in the glomeruli of the DM and DM+GW0742 groups. Original magnification 3400. D: Localization of renal Bcl-6 protein expression by immunohistochemistry. Bcl-6 protein was mainly expressed in the glomeruli of the control group, but its expression was suppressed in the DM group. The expression of Bcl-6 recovered in the DM+GW0742 groups compared with the DM group. Original magnification 3400. (A high-quality digital representation of this figure is available in the online issue.) inducing diabetes. The kidneys were removed, weighed, and fixed in 10% formalin for periodic acid-methenamine silver (PAM) staining, and parts of the remaining tissues were embedded in optimal cutting temperature compound (Sakura Finetechnical, Tokyo, Japan) and frozen immediately in acetone cooled on dry ice. Other tissues were snap-frozen in liquid nitrogen and stored at 280°C. Metabolic data. We measured body weight, blood pressure, hemoglobin A 1c (HbA 1c ), 24-h urinary albumin excretion (UAE), and creatinine clearance at 0, 4, and 8 weeks. Blood pressure was measured using the tail-cuff method (Softron, Tokyo, Japan). HbA 1c was measured using the high-pressure liquid chromatography method, and serum creatinine was measured using the enzymatic method. Urine was collected for 24 h, with each mouse individually housed in a metabolic cage and provided with food and water ad libitum. Urinary albumin concentration was measured as previously described (9) . Creatinine was measured enzymatically, and creatinine clearance was calculated. Light microscopy. PAM-stained sections were analyzed. To evaluate glomerular size, we examined 10 randomly selected glomeruli in the cortex per animal under high magnification (3400) at 8 weeks after induction of diabetes. The area of the glomerular tuft and the mesangial matrix index (MMI) were measured using Lumina Vision software (Mitani Corporation, Tokyo, Japan). MMI was defined as the PAM-positive area in the tuft area, calculated using the following formula: MMI = (PAM positive area)/(tuft area). The results are expressed as means 6 SE (per mm 2 for tuft area; arbitrary units for MMI). Immunoperoxidase staining. Immunoperoxidase staining was performed as previously described (9) . Briefly, fresh frozen sections were cut to 4 mm thick using a cryostat. To evaluate macrophage infiltration, we applied a rat antimouse monocyte/macrophage (F4/80) monoclonal antibody (Abcam, Tokyo, Japan), followed by biotin-labeled goat antirat IgG antibody (Jackson Immunoresearch Laboratories, West Grove, PA). The avidin-biotin coupling reaction was performed on sections using a Vectastain Elite kit (Vector Laboratories, Burlingame, CA). We examined 10 glomeruli per animal and counted the number of F4/80-positive cells. The mean number of positive cells per glomerulus and interstitial tissue (number per mm 2 ) were used for the estimation. To evaluate PPARd and Bcl-6 expression, PPARd rabbit polyclonal antibody (Affinity BioReagents, Golden, CO) and Bcl-6 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) were applied, followed by biotinlabeled donkey anti-rabbit IgG antibody (Jackson Immunoresearch Laboratories). Immunofluorescent staining. Immunofluorescent staining was performed as previously described (9) . To clarify the differences in mesangial matrix proteins, we used rabbit anti-type IV collagen antibody (Millipore, Temecula, CA), followed by Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, Carlsbad, CA). Fluorescence pictures were obtained using a fluorescence microscope (BX51; Olympus, Tokyo, Japan). The type IV collagen immunofluorescence intensity was quantified as previously described (9) . Briefly, using Lumina Vision software (Mitani Corporation), the intensity of expression on the images was calculated using the formula, x (density) 3 positive area (mm 2 ). The positive area of type IV collagen in each glomerulus was estimated as the ratio to the mean area of the glomerulus. Ten glomeruli per animal were evaluated. Quantitative analysis of renal cortex gene expression. The RNA from the renal cortex was isolated 8 weeks after treatment using an RNeasy Mini Kit (Qiagen, Valencia, CA). Single-strand cDNA was synthesized from the extracted RNA using a RT-PCR kit (Perkin Elmer, Foster City, CA). To evaluate the mRNA expression of PPARd, CD14, CD11c, monocyte chemoattractant protein (MCP)-1, chemokine CC motif receptor 2 (CCR2), TGF-b, tumor necrosis factor (TNF)-a, osteopontin (OPN), and ICAM-1 in the renal cortex, quantitative RT-PCR (qRT-PCR) was performed using StepOnePlus (Applied Biosystems, Tokyo, Japan) and FastStart SYBR Premix Ex Taq II (Takara Bio, Otsu, Japan). The primers were purchased from Takara Bio. Each sample was analyzed in triplicate and normalized for GAPDH mRNA expression. Cell culture and treatment. RAW 264.7 murine macrophages were cultured in Dulbecco's modified Eagle's medium supplemented with 1,000 mg/L D-glucose, 10% FBS, 100 units/mL penicillin, 100 mg/mL streptomycin, and 2 mmol/L L-glutamine. For ligand treatment, cells were serum-starved by culture in 0.5% FBS for 24 h. After pretreatment with GW0742 (10 mmol/L) for 24 h, the cells were stimulated with 4,500 mg/L D-glucose (high glucose) for 24 h. Individual experiments were repeated at least three times with different lots or preparation of cells. Quantitative analysis of gene expression in RAW macrophages. Total RNA was prepared from cells using an RNeasy Mini Kit (Qiagen) as described above. B-cell lymphoma-6 (Bcl-6), MCP-1, and OPN mRNA expression in RAW macrophages was measured using qRT-PCR, as described above. Immunoprecipitation and Western blotting. Bcl-6 and PPARd protein expression levels were determined by Western blotting. To examine the interactions between PPARd and Bcl-6, the nuclear protein fraction was isolated from RAW macrophages using a Nuclear Extract Kit (Active Motif, Carlsbad, CA). The nuclear protein was immunoprecipitated with an anti-PPARd antibody (Affinity BioReagents) for 1.5 h at 4°C. The nuclear protein-antibody complex was then incubated with magnetized Protein G Dynabeads (Invitrogen) for 45 min at room temperature. After washing the beads, the bound proteins were eluted and resolved by SDS-PAGE. Protein was transferred to nitrocellulose membranes and blocked in 20 mmol/L Tris-HCl (pH 7.6) containing 150 mmol/L NaCl, 0.1% Tween-20, and 5% (wt/vol) nonfat dried milk. The blots were then incubated with anti-PPARd antibody (Affinity BioReagents) and anti-Bcl-6 antibody (Santa Cruz Biotechnology). The immunoblots were hybridized with anti-TATA binding protein antibody (Abcam) to monitor equivalent loading in different lanes. All experiments were repeated at least three times. Statistical analysis. All values are means 6 SE. Statistically significant differences between groups were examined using one-way ANOVA followed by Scheffé test. A P value ,0.05 was considered statistically significant.
RESULTS

Metabolic data and time course of changes in UAE.
The UAE progressively increased in diabetic mice during the study (Fig. 1A) . However, GW0742 treatment significantly reduced the mean UAE (86.09 6 12.67 mg/day) compared with the DM group at 8 weeks after inducing diabetes (40.91 6 3.94 mg/day; P , 0.01). The other metabolic data are summarized in Table 1 . Eight weeks after inducing diabetes, there were no significant differences in systolic blood pressure between the three groups. HbA 1c , kidney weight, and relative kidney weight were significantly higher in the DM group than in the control group. There was no significant difference in HbA 1c , kidney weight, and relative kidney weight between the DM and the DM+GW0742 groups. Body weight was lower in both the DM and the DM+GW0742 groups than in the control, but was higher in the DM+GW0742 than in the DM group. There were no significant differences in creatinine clearance or triglyceride levels between the three groups. Renal PPARd and Bcl-6 expression. We found PPARd mRNA and protein expression in the kidneys. At 8 weeks, 
PPAR-d AGONIST AMELIORATES DIABETIC NEPHROPATHY
renal PPARd mRNA expression was significantly greater in the DM group than in the control group (0.71 6 0.18 vs. 0.24 6 0.07, respectively; P , 0.05) (Fig. 1B) . However, GW0742 treatment did not affect PPARd mRNA expression in renal tissues. Renal sections immunostained with PPARd-specific antibodies revealed that PPARd protein expression was predominantly localized in the glomeruli of DM and DM+GW0742 groups and to a lesser extent in the glomeruli of the control group (Fig. 1C) . By contrast, the anti-inflammatory corepressor Bcl-6 was mainly expressed in the glomeruli of the control group, and its expression was suppressed in the DM group. GW0742 treatment recovered the expression of Bcl-6 compared with the DM group (Fig. 1D) . MMI and expression of type IV collagens in the glomeruli. Representative glomeruli in PAM-stained sections are shown in Fig. 2A . Glomerular hypertrophy and mesangial matrix expansion were observed in the DM group at the end of the 8-week observation period. However, these changes were ameliorated in the DM+GW0742 group compared with DM group (MMI: 9.05 6 0.30 vs. 12.34 6 0.49%, respectively; P , 0.001) (Fig. 2B) . A similar trend was noted for type IV collagen (Fig. 2C) . The type IV collagen-positive area in glomeruli was larger in the DM group than in the control group. This area was markedly reduced in the DM+GW0742 group compared with the DM group (9.57 6 0.18 vs. 12.33 6 0.49%, respectively; P , 0.001) (Fig. 2D) . Macrophage infiltration in the kidney. The number of macrophages in the glomeruli was remarkably higher in the DM group than in the control group. Interestingly, macrophage infiltration into the glomeruli was significantly reduced in the DM+GW0742 group compared with the DM group (1.80 6 0.08 vs. 2.69 6 0.05, respectively; P , 0.001) ( Fig. 3A and B) . Similarly, macrophage infiltration into the interstitium was increased in the DM group but was suppressed in the DM+GW0742 group (13.79 6 0.53 vs. 7.75 6 0.77, respectively; P , 0.001) (Fig. 3A and C) . Macrophage and inflammatory gene expression in the renal cortex. qRT-PCR analyses of kidney tissue demonstrated that the expression of two macrophage marker genes, CD14 and CD11c, was increased in the DM group and that GW0742 treatment markedly reduced the expression of these genes (Fig. 4) . CD14 is a marker for all macrophages, and CD11c is specific for the M1 subtype of macrophages. Similarly, the induction of diabetes increased the renal expression of several proinflammatory and proatherogenic genes, including MCP-1, TGF-b, OPN, TNF-a, and ICAM-1. Although GW0742 decreased the expression of MCP-1, TGF-b, and OPN, it did not affect TNF-a or ICAM-1 (Fig. 4) . Of note, MCP-1, a key chemokine involved in macrophage recruitment, plays a significant role in diabetic nephropathy because the absence of MCP-1 significantly reduces diabetic renal injury (18, 19) . Similarly, OPN is also a critical inflammatory cytokine involved in diabetic nephropathy (20, 21) . Collectively, these data indicate that the PPARd agonist GW0742 inhibits diabetes-induced macrophage recruitment and inflammatory gene expression in the kidney.
PPARd and Bcl-6 expression in RAW macrophages. PPARd has been demonstrated to directly affect the antiinflammatory transcriptional repressor Bcl-6. PPARd agonists increase free Bcl-6 in macrophages, suppressing MCP-1 transcription and decreasing macrophage infiltration (22) . To investigate the regulation of renal inflammatory pathways by diabetes and PPARd, and the roles of Bcl-6 and PPARd in these processes, we performed in vitro studies using RAW macrophages. qRT-PCR analyses revealed that the high-glucose medium strongly inhibited Bcl-6 expression in RAW macrophages and that GW0742 treatment significantly attenuated this inhibition in macrophages (Fig. 5A) . We found that macrophages exposed to high glucose had an increase in nuclear PPARd protein and that pretreatment with GW0742 completely abolished this effect (Fig. 5B) . Western blot analyses of total and PPARd-bound Bcl-6 in macrophage nuclear extracts revealed that high glucose tended to suppress total Bcl-6 but markedly increased PPARd-Bcl-6 complexes and that GW0742 pretreatment decreased PPARd-Bcl-6 binding (Fig. 5C ). These data indicate that high glucose can increase nuclear PPARd-Bcl-6 binding, limiting the amount of free Bcl-6 available to repress the expression of inflammatory genes normally suppressed by Bcl-6.
Inflammatory gene expression in RAW macrophages.
To further investigate the role of PPARd activation in inflammatory processes, we examined the effects of GW0742 on inflammatory gene expression in macrophages. Consistent with the changes in free Bcl-6, high glucose-stimulated MCP-1 expression, which is regulated by Bcl-6, was attenuated by GW0742 (Fig. 6A) . The expression of OPN, a macrophage chemokine, was also increased by exposure to high glucose and suppressed by GW0742 (Fig. 6B) .
DISCUSSION
In the current study, we demonstrated that the PPARd agonist GW0742 ameliorated albuminuria, glomerular mesangial expansion, and type IV collagen accumulation without affecting blood glucose levels in STZ-induced Similarly, GW0742 suppressed MCP-1, CCR-2, TGF-b, and OPN mRNA levels in the kidney. mRNA levels are normalized to GAPDH. Data are means 6 SE. *P < 0.05. diabetic mice. GW0742 treatment markedly decreased macrophage infiltration in diabetic kidney and the expression of inflammatory genes, including MCP-1, TGF-b, and OPN. Furthermore, in vitro studies with RAW macrophages revealed that high glucose suppressed the expression of free Bcl-6, which was associated with increased expression of MCP-1 and OPN, and that GW0742 reversed these effects. Our findings suggest that the activation of PPARd Bcl-6 expression was normalized to GAPDH. Data are means 6 SE. *P < 0.05. B: High glucose increases and GW0742 decreases macrophage PPARd protein expression. PPARd expression was normalized to that of TBP. Data are means 6 SE. *P < 0.05. C: Bcl-6 protein expression and PPARd-Bcl-6 interaction in macrophages in response to high glucose and/or GW0742. The Bcl-6-PPARd interaction was analyzed by Western blotting of total and PPARd-bound Bcl-6 in macrophage nuclear proteins after pull-down assays. Bcl-6 expression was normalized to that of TBP. Data are means 6 SE. *P < 0.05. has an anti-inflammatory effect in diabetic kidneys and prevents the development of nephropathy, independently of blood glucose levels. The nuclear receptor transcription factors PPARg, PPARa, and PPARd are critical in regulating insulin sensitivity, adipogenesis, lipid metabolism, and inflammation (11) . All three PPAR isoforms have been proposed as therapeutic targets for the treatment of metabolic syndrome, dyslipidemia, and diabetes (11) . Several recent clinical studies have provided evidence that thiazolidinedione, PPARg agonists, and fibrates, PPARa agonists, confer a renoprotective effect in patients with type 2 diabetes (23) (24) (25) . Experimental studies have also shown beneficial effects of PPARg agonists on renal injury in type 1 and type 2 diabetic animal models, and multiple mechanisms seem to be involved (26, 27) . We previously demonstrated that the PPARg agonist pioglitazone ameliorates diabetic nephropathy by inhibiting cell cycle-dependent hypertrophy of podocytes by reducing Bcl-2 and p27Kip1 protein levels (13) and by suppressing ICAM-1 expression and macrophage infiltration by inhibiting nuclear factor-kB activation in endothelial cells (14) . PPARa agonists also have renoprotective effects by reducing TGF-b and plasminogen activator inhibitor-1 expression in mesangial cells (15) . However, unlike PPARg and PPARa, little is known about the therapeutic potential of PPARd agonists in diabetic nephropathy.
Many studies have proposed an important role of inflammatory processes in the pathogenesis of diabetic nephropathy (6,7). We previously reported macrophage infiltration and increased expression of leukocyte adhesion molecules in the kidneys of patients with diabetic nephropathy in addition to mesangial matrix expansion and interstitial fibrosis (8). We have also described the importance of ICAM-1-dependent infiltration of macrophages into the kidney in the pathogenesis of diabetic nephropathy in a series of studies (9, 28) . Furthermore, we have demonstrated that SR-A-deficient mice are protected from renal injury after induction of diabetes by inhibiting macrophage migration into diabetic kidneys (10) . Other studies have reported that the chemokine MCP-1 plays an important role in the pathogenesis of diabetic nephropathy (29) . The importance of MCP-1 in the early development of diabetic nephropathy has been determined using animal models incorporating genetically deficient mice or therapeutic blockade of the MCP-1 receptor CCR2 (18, 19, 30 ). In the current study, MCP-1 expression in the kidney was increased in diabetic mice and suppressed by the administration of GW0742. PPARd activation has been suggested to reduce MCP-1 and subsequently reduces the number of recruited macrophages in diabetic glomeruli and interstitium.
In this study, we found that diabetes significantly increased PPARd expression in the kidney, and that high glucose increased PPARd expression in cultured RAW macrophages. In contrast to our observations, Yu et al. (31) reported a decrease in PPARd gene and protein expression in the myocardium of diabetic rats. On the other hand, several investigators observed an increase in PPARd expression in the lung (32) , diaphragm (33) , and aorta (16) in diabetic animals. Taken together, these results suggest that PPARd expression in the diabetic state differs between individual tissues and may depend on the balance between the two major fuel utilization pathways (i.e., glucose vs. fatty acid metabolism and their cross-talk) (33) . The mechanisms by which high glucose increases the expression of PPARd remain unclear, and further studies are needed.
Unliganded PPARd, which binds to the anti-inflammatory transcriptional repressor Bcl-6, reduces the amount of free Bcl-6 available to suppress MCP-1 transcription, thus increasing MCP-1 expression (22) . We showed that administration of the PPARd agonist GW0742 substantially attenuated STZ-induced diabetic nephropathy without altering the blood glucose level and increased the renal expression of Bcl-6, which was associated with suppression of MCP-1 gene expression in the kidney. We have searched for the PPRE in the promoter region of Bcl-6, but have been unable to locate any PPRE sites. Thus, we speculate that activation of PPARd may induce other transcriptional factors, which induce Bcl-6 gene expression. Moreover, immunoprecipitation and Western blotting revealed that high glucose increased the PPARd-Bcl-6 complex, reducing the amount of free Bcl-6 in cultured macrophages. Activation of PPARd by GW0742 decreased PPARd-Bcl-6 binding and increased the amount of free Bcl-6, which consecutively decreased MCP-1 expression in macrophages. Based on these in vivo and in vitro data, inhibition of MCP-1 expression by PPARd agonists is likely mediated through increased expression of Bcl-6 (Fig. 7) .
OPN acts as a chemokine and as a proinflammatory cytokine (34) . We previously demonstrated that OPN expression was increased in diabetic kidneys and suppressed by SR-A deficiency (10) . Other studies have shown that OPN is expressed in renal resident cells and is regarded as a key molecule in the pathogenesis of diabetic nephropathy (20, 21) . In this study, consistent with the changes in MCP-1 expression, high glucose-induced OPN expression in macrophages was attenuated by GW0742. Therefore, inhibition of OPN expression by PPARd agonists may contribute, at least in part, to the beneficial renal effects of PPARd agonists in diabetic nephropathy.
In conclusion, the data presented in this study indicate that PPARd activation attenuates high glucose-induced expression of MCP-1 and OPN by increasing the antiinflammatory repressor Bcl-6 in macrophages. The PPARd agonist GW0742 shows renoprotective effects through its anti-inflammatory activity by inhibiting MCP-1 expression and macrophage infiltration in the diabetic kidney. Because MCP-1 is a key component in the inflammatory response and the recruitment of monocytes/macrophages into the diabetic kidney, inhibition of MCP-1 expression by PPARd agonist could provide a potential therapeutic target in human diabetic nephropathy.
